CGT Global Appoints Charlotte Ivancic to Board of Advisors, Strengthening Strategic Leadership in Cell and Gene Therapy Policy and Market Access

Key Takeaways

• Ivancic adds 25+ years of federal health policy experience to CGT
• CGT aims to align gene therapy reimbursement with Medicare, Medicaid
• Outpatient delivery models could lower costs and expand patient access
• Board addition signals CGT’s focus on regulatory and legislative strategy
• Industry expects policy guidance to accelerate scaling of advanced therapies

Pulse Analysis

The cell and gene therapy market is at a tipping point, with clinical breakthroughs outpacing the infrastructure needed for widespread adoption. Payers, especially Medicare and Medicaid, remain cautious about covering high‑price treatments, creating a reimbursement bottleneck that can stall commercial rollout. Companies are therefore looking beyond scientific innovation to redesign care pathways, emphasizing outpatient administration and value‑based contracts that align costs with outcomes.

Charlotte Ivancic’s appointment brings a rare blend of Capitol Hill experience and health‑policy expertise to CGT Global. Having helped shape Medicare payment reforms and value‑based care models, she is positioned to influence how regulators and legislators view advanced therapies. Her role on the Board of Advisors signals CGT’s intent to proactively engage policymakers, ensuring that reimbursement frameworks evolve in step with therapeutic advances, and that the company can offer clearer pathways for its partners.

For the broader biotech ecosystem, this strategic hire highlights the growing importance of policy navigation as a core competency. As more gene‑editing and cell‑based products enter late‑stage trials, firms that can align clinical data with payer expectations will secure faster market entry and more sustainable pricing. Ivancic’s guidance could accelerate the adoption of outpatient delivery models, reduce overall treatment costs, and ultimately expand patient access to life‑saving therapies, setting a precedent for other innovators seeking to bridge the gap between breakthrough science and real‑world impact.